JP2022529518A5 - - Google Patents
Info
- Publication number
- JP2022529518A5 JP2022529518A5 JP2021563139A JP2021563139A JP2022529518A5 JP 2022529518 A5 JP2022529518 A5 JP 2022529518A5 JP 2021563139 A JP2021563139 A JP 2021563139A JP 2021563139 A JP2021563139 A JP 2021563139A JP 2022529518 A5 JP2022529518 A5 JP 2022529518A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently selected
- groups
- compound according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838696P | 2019-04-25 | 2019-04-25 | |
| US62/838,696 | 2019-04-25 | ||
| PCT/US2020/029849 WO2020219904A1 (en) | 2019-04-25 | 2020-04-24 | Heterocyclic inhibitors of tyrosine kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529518A JP2022529518A (ja) | 2022-06-22 |
| JP2022529518A5 true JP2022529518A5 (enExample) | 2023-05-02 |
| JP7601788B2 JP7601788B2 (ja) | 2024-12-17 |
Family
ID=72941423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563139A Active JP7601788B2 (ja) | 2019-04-25 | 2020-04-24 | チロシンキナーゼの複素環式阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11365189B2 (enExample) |
| EP (1) | EP3962908A4 (enExample) |
| JP (1) | JP7601788B2 (enExample) |
| CN (2) | CN114026083B (enExample) |
| AU (1) | AU2020261423B2 (enExample) |
| CA (1) | CA3137901A1 (enExample) |
| WO (1) | WO2020219904A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12145917B2 (en) | 2018-12-06 | 2024-11-19 | Arthrosi Therapeutics, Inc. | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
| EP3962908A4 (en) | 2019-04-25 | 2022-10-26 | Board of Regents, The University of Texas System | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE |
| WO2021127397A1 (en) * | 2019-12-19 | 2021-06-24 | Black Diamond Therapeutics, Inc. | Nitrogen heterocyclic compounds and methods of use |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| WO2022225238A1 (ko) * | 2021-04-22 | 2022-10-27 | 보로노이 주식회사 | 헤테로아릴 유도체 화합물 및 이의 용도 |
| WO2022266426A1 (en) * | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | 6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof |
| WO2022266425A1 (en) * | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | 3-cyano-quinoline derivatives and uses thereof |
| IL310870A (en) * | 2021-08-24 | 2024-04-01 | Arthrosi Therapeutics Inc | Quinazoline compounds for treatment of disease |
| CN115894486B (zh) * | 2021-09-30 | 2024-02-09 | 北京赛特明强医药科技有限公司 | 一种氢化吡啶并喹唑啉类化合物、组合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4776882B2 (ja) * | 2002-03-30 | 2011-09-21 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 二環式複素環化合物、これらの化合物を含む医薬組成物、それらの使用及びそれらの調製方法 |
| TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| KR101217526B1 (ko) | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
| CN104513229A (zh) * | 2013-09-28 | 2015-04-15 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物及其制备方法 |
| CN106068262B (zh) * | 2014-04-11 | 2019-10-29 | 海思科医药集团股份有限公司 | 喹唑啉衍生物及其制备方法和在医药上的应用 |
| WO2016150340A1 (zh) * | 2015-03-20 | 2016-09-29 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物的盐及其制备方法 |
| JP7036798B2 (ja) * | 2016-08-25 | 2022-03-15 | 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 | キナゾリン誘導体の塩の結晶 |
| CN112040952B (zh) * | 2018-02-20 | 2023-03-31 | 苏州韬略生物科技股份有限公司 | 用作激酶抑制剂的取代的喹啉 |
| EP3962908A4 (en) | 2019-04-25 | 2022-10-26 | Board of Regents, The University of Texas System | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE |
-
2020
- 2020-04-24 EP EP20796402.4A patent/EP3962908A4/en active Pending
- 2020-04-24 CA CA3137901A patent/CA3137901A1/en active Pending
- 2020-04-24 CN CN202080045535.4A patent/CN114026083B/zh active Active
- 2020-04-24 WO PCT/US2020/029849 patent/WO2020219904A1/en not_active Ceased
- 2020-04-24 CN CN202410871766.0A patent/CN118852118A/zh active Pending
- 2020-04-24 AU AU2020261423A patent/AU2020261423B2/en active Active
- 2020-04-24 US US16/858,116 patent/US11365189B2/en active Active
- 2020-04-24 JP JP2021563139A patent/JP7601788B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529518A5 (enExample) | ||
| JP2025525406A5 (enExample) | ||
| JP2024100974A5 (enExample) | ||
| JP2021514001A5 (enExample) | ||
| JP2024050527A5 (enExample) | ||
| JP2021523200A5 (enExample) | ||
| JP2022551185A5 (enExample) | ||
| JP2024514837A5 (enExample) | ||
| JP2012529535A5 (enExample) | ||
| JP2012500260A5 (enExample) | ||
| RU2017121906A (ru) | Конъюгаты цистеамина и жирной кислоты и их применение в качестве активаторов аутофагии | |
| JP2019034943A5 (enExample) | ||
| CN111094242A (zh) | 用于治疗与nlrp活性相关的病症的化合物和组合物 | |
| JP2012526728A5 (enExample) | ||
| JP2018519302A5 (enExample) | ||
| JP2021527638A5 (enExample) | ||
| JP2023520925A5 (enExample) | ||
| JP2020502047A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2007516983A5 (enExample) | ||
| JP2024524766A5 (enExample) | ||
| JP2022548247A5 (enExample) | ||
| JP2023164918A5 (enExample) | ||
| JP2024545787A5 (enExample) | ||
| JP2023526050A5 (enExample) |